Adj. EBITA SEK 180m (-16% vs. ABGSCe 214m) Consensus full-year EBITA should come down by mid-to-high...
Redeye comments on Safeture's Q1 2024 report, which was stable despite higher churn.
Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and ...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye is encouraged to see progress in Impact Coatings’ Chinese coating center.
Q1e: Clean EBIT of PLN 87m Paper is improving – better demand and 10% supply cuts Fair value range o...
'24e-'26e ARR cut by 2-3% on continued macro weakness B2C business momentum likely to return in H2'2...
Solid Q1 with 33% ARR growth and 15% adj. EBITDA margin Raising '24e-'26e ARR by ~1%, EBITDA by 19-1...
Försäljningen i Q4 minskade något jämfört med samma period i fjol.
Inför Q1: marknadsdata indikerar underliggande tillväxt i Sverige Vi förväntar oss en omsättningstil...
Q1: 33% y-o-y ARR growth and 15% adj. EBITDA margin All FY'24 guidance items upgraded once again Con...
The recorded sales growth is 0% in local currency due to an extended headwind for the Genetics busin...
SRV publishes its Q1/24 figures on Thursday 25th of April.
Consti reports its Q1/24 results on 25th of April. We expect continued sales decline during the seas...
Redeye leaves an initial comment following the Q1 report published by Magle this morning.
Redeye provides its initial take on Vitec’s Q1 2024 report, which came in slightly below our estimat...
Redeye provides its initial take on ADDvise’s Q1 2024 report, which came in broadly below our estima...
Hansa’s Q1 result includes a positive outlook in 2024 supported by additional countries and the Euro...
We lower '24e-'26e adj. EBITA by 10-3%... ...on continued weakness in macro data '24e EV/EBITA of ~8...
Positive order intake momentum Outdoor demand rebound during Q3e '24e-'26e EBIT up 3-2% Positive mo...
